Tag: Lung Cancer

[Articles] Global variations in lung cancer incidence by histological subtype in 2020: a population-based study

AI SummaryAdenocarcinoma is now the most common type of lung cancer worldwide, especially in males. This information helps guide preventive measures in different regions.Adenocarcinoma has become the most common subtype of lung cancer globally in 2020, with incidence rates in males exceeding those of squamous cell carcinoma in most countries, and in females in all… Continue reading [Articles] Global variations in lung cancer incidence by histological subtype in 2020: a population-based study

Capturing immunotherapy response in a blood drop

AI SummaryLiquid biopsies can help identify advanced lung cancer patients who could benefit from additional drugs.Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells). When used in patients with advanced non-small cell lung cancer undergoing immunotherapy, they may identify patients… Continue reading Capturing immunotherapy response in a blood drop

Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self‐reporting as Indigenous and non‐Indigenous

Abstract Background Lung cancer is the leading cause of cancer deaths. Screening individuals who are at elevated risk using low-dose computed tomography reduces lung cancer mortality by ≥20%. Individuals who have community-based factors that contribute to an increased risk of developing lung cancer have high lung cancer rates and are diagnosed at younger ages. In… Continue reading Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self‐reporting as Indigenous and non‐Indigenous

Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self‐reporting as Indigenous and non‐Indigenous

Abstract Background Lung cancer is the leading cause of cancer deaths. Screening individuals who are at elevated risk using low-dose computed tomography reduces lung cancer mortality by ≥20%. Individuals who have community-based factors that contribute to an increased risk of developing lung cancer have high lung cancer rates and are diagnosed at younger ages. In… Continue reading Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self‐reporting as Indigenous and non‐Indigenous

Development of Trisubstituted Thiophene-3-Carboxamide Selenide Derivatives as Novel EGFR Kinase Inhibitors with Cytotoxic Activity

Overexpression of EGFR is one of the eminent oncogenic drivers detected in the development of several human cancers. The increasing incidences of mutation-based resistance in the tyrosine kinase domain call upon the need for the development of a newer class of small-molecule TK inhibitors. Accordingly, a new series of symmetrical trisubstituted thiophene-3-carboxamide selenide derivatives was… Continue reading Development of Trisubstituted Thiophene-3-Carboxamide Selenide Derivatives as Novel EGFR Kinase Inhibitors with Cytotoxic Activity

Giving Voice to the Need for Robust Cancer Research Funding

AI SummaryEdward Cutler, a cancer survivor, participated in the Rally for Medical Research Hill Day to advocate for increased funding for cancer research. He shared his story of successful treatment through experimental drugs and emphasized the importance of federal investment in research. Cutler, along with other advocates and early-career researchers, met with lawmakers to encourage… Continue reading Giving Voice to the Need for Robust Cancer Research Funding

Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy

AI Summary[18F]DK222-PET is a potential non-invasive tool for monitoring the effects of immunotherapy on tumors. It can detect PD-L1 expression in tumors and quantify therapy-induced changes. It can also differentiate the impact of different therapies on tumors.Background Combination therapies that aim to improve the clinical efficacy to immune checkpoint inhibitors have led to the need… Continue reading Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy